Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-003293
Filing Date
2025-07-31
Accepted
2025-07-31 16:37:15
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12244
2 JOINT FILING AGREEMENT p25-1674exhibit99_1.htm EX-99.1 4173
  Complete submission text file 0000902664-25-003293.txt   18433
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Subject) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-50777 | Film No.: 251172229
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020
Business Address 1 ROCKEFELLER PLAZA, SUITE 1205 NEW YORK NY 10020 212-608-3300
Empery Asset Management, LP (Filed by) CIK: 0001469336 (see all company filings)

EIN.: 262107121 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G